Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) vs penicillamine in Wilson's disease
2016-003876-29Phase 3Completed
- Sponsor
- Orphalan
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of trientine tetrahydrochloride in Wilson disease (WD) (2 arms), sponsored by Orphalan. Primary endpoint: Serum non-ceruloplasmin-bound copper (NCC) at week 36. Started Mar 2017; status: completed.
02
Drugs
trientine tetrahydrochloride
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2016-003876-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003876-29.